Immorta Bio files Form D for $5 million equity offering
The Delaware biotechnology company reported $612,503 raised from six investors as of a filing dated October 16, 2026.
Immorta Bio, Inc., a Delaware corporation incorporated in 2023 and based in Miami Beach, Florida, filed a Form D notice with the Securities and Exchange Commission disclosing an exempt securities offering. The issuer is identified as Immorta Bio, Inc., incorporated in Delaware within the last five years, specifically in 2023.1 The company classified its industry as biotechnology within the health care sector.1
The filing is a new notice with a date of first sale listed as November 5, 2024.1 Immorta Bio claimed the Rule 506(c) exemption under federal securities law.1 The securities offered are equity.1
The total offering amount is listed at $5,000,000, with total amount sold reported as $612,503 and $4,387,497 remaining to be sold.1 The minimum investment accepted from any outside investor is $45,000.1 The filing states a total of 6 investors have already invested in the offering.1
The company reported $0 in sales commissions and $0 in finders' fees.1 The filing also lists $0 in proceeds used for payments to executive officers, directors, or promoters.1
Boris Reznik, located at the same Miami Beach address, is listed as a related person with the relationship designated as Executive Officer.1 The issuer reported no revenues and no aggregate net asset value.1
The notice was signed by Brian Chaiken, identified as General Counsel, with a signature date of October 16, 2026.1 The issuer indicated it intends the offering to last more than one year.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.